Development and impact of human papillomavirus vaccines.
Obstetrics & Gynecology, Oncology
Clinical obstetrics and gynecology
Culture, Female, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Humans, Male, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Socioeconomic Factors, Uterine Cervical Neoplasms
Cervical cancer is a global health crisis that disproportionately affects developing nations and underserved populations. Two vaccines targeting HPV-16 and 18, which account for 70% of invasive cervical carcinomas, are licensed in the United States and numerous countries worldwide. Both vaccine formulations have shown excellent efficacy with minimal toxicity. Numerous questions remain, including cost-effectiveness, vaccination of males, societal acceptance of HPV vaccination, and cervical dysplasia screening in the HPV-immunized population. Access to vaccination for underserved populations both in developed and resource-poor nations remains an issue. Multivalent vaccines that encompass additional oncogenic HPV strains are under development.
Darus, Christopher J and Mueller, Jennifer J, "Development and impact of human papillomavirus vaccines." (2013). Maine Medical Center. 2041.